Gamma-delta T cells in neuroblastoma: Exploiting MHC-independent recognition to overcome the barriers of high-risk disease
Year: 2026
Type: review
Abstract: Neuroblastoma is the most frequent extracranial solid tumor in children and the main cause of early childhood cancer deaths. Relapse occurs in more than half of high-risk patients despite rigorous multimodal therapy, and four-year overall survival in relapsed disease is approximately 20%. Anti-GD2 monoclonal antibodies and GD2-directed CAR T cell treatment have advanced the field, although neither has eliminated neuroblastoma's immune resistance. Current immunotherapy has three interrelated challenges. GD2 heterogeneity lets antigen-negative subclones escape and cause recurrence. Inhibitory cytokines, regulatory T cells, and myeloid-derived suppressor cells dominate the TME. MHC class I downregulation frequently renders traditional αβ T cell methods ineffective, even with the target antigen present. Gamma-delta (γδ) T cells offer a distinct mechanism. They recognize tumor targets without antigen presentation by sensing stress-induced ligands through NKG2D and DNAM-1 and phosphoantigens through butyrophilin proteins BTN3A1 and BTN2A1. This recognition holds regardless of MHC class I status. In conjunction with anti-GD2 antibodies, CD16 expression boosts antibody-dependent cellular cytotoxicity. In neuroblastoma lesions, γδ T cells are the primary antitumoral fraction in tumor-infiltrating lymphocyte products, indicating compatibility with the disease's immune system. This study examines neuroblastoma immunotherapy failure mechanisms and innovative γδ T cell platforms, such as non-engineered allogeneic products, composite γδ T plus NK cell techniques, and CAR- and AbTCR-modified designs. A biomarker-driven patient selection paradigm and product standardization, in vivo persistence, and TME suppression are examined. NCT05400603, the first trial of adoptive transfer of ex vivo-expanded allogeneic γδ T cells in a population that includes pediatric neuroblastoma patients, is crucial for proving the mechanism.
Source: Translational Oncology
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: γδ T cells, neuroblastoma, MHC-independent antigen recognition, stress-induced ligands, NKG2D, DNAM-1, phosphoantigens, BTN3A1, BTN2A1, tumor-infiltrating lymphocytes, anti-GD2 antibody, chimeric antigen receptor T cells, tumor microenvironment, immunotherapy resistance, high-risk neuroblastoma, childhood cancer
Open Access status: gold
Estimated APC paid: $3,390
OpenAlex ID: W7234031947
